Search

Your search keyword '"Toplak, H."' showing total 323 results

Search Constraints

Start Over You searched for: Author "Toplak, H." Remove constraint Author: "Toplak, H."
323 results on '"Toplak, H."'

Search Results

51. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial

52. New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk. Statement of the D center dot A center dot CH Society for Prevention of Cardiovascular Diseases, the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society for Cardiology

53. New AHA- and ACC-Guidelines for Risk Reduction of Cardio-Vascular-Disease by lowering Cholesterol. Measures of the D.A.CH-Prevention Society of Cardio-Vascular-Diseases e.V., the Austrian Atherosclerosis Society and the Study Group of Lipids and Atherosclerosis (AGLA) of the Swiss Society of Cardiology (vol 55, pg 601, 2014)

54. [Evaluation of a newly discovered LDL receptor mutation (exon 10, GACAAC, D271N, 'FH Graz-1') in familial hypercholesterolemia-- a familystudy]

73. Effect of acarbose on weight maintenance after dietary weight loss in obese subjects*.

78. Neue AHA- und ACC-Leitlinie zur Risikoreduktion von Herz-Kreislauf-Erkrankungen durch Cholesterinsenkung

79. [Insulin-sulfonylurea combination therapy in secondary therapy failure with sulfonylurea compounds. Randomized study between evening and morning intermediary insulin administration using the Novo Pen semi-automatic insulin injector]

80. European practical and patient-centred guidelines for adult obesity management in primary care

86. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

88. Obesity and cardiovascular risk

89. Effect of acarbose on weight maintenance after dietary weight loss in obese subjects*.

91. Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity part B obesity-induced cardiovascular disease, early prevention strategies and future research directions

92. Joint scientific statement of the European Association for the Study of Obesity and the European Society of Hypertension: Obesity and early vascular ageing

93. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and heart failure

94. The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.

95. Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.

96. Use of combination therapy is associated with improved LDL-cholesterol management: 1-year follow-up results from the European observational SANTORINI study.

97. Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study.

98. [Overweight and obesity in adults: general principles of treatment and conservative management].

99. Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients.

100. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study.

Catalog

Books, media, physical & digital resources